Last updated: 20 June 2019 at 2:57am EST

Christopher Bartlett Net Worth




The estimated Net Worth of Christopher Bartlett is at least $4.05 Million dollars as of 24 May 2005. Christopher Bartlett owns over 15,000 units of Resmed stock worth over $4,046,720 and over the last 21 years Christopher sold RMD stock worth over $0.

Christopher Bartlett RMD stock SEC Form 4 insiders trading

Christopher has made over 1 trades of the Resmed stock since 2005, according to the Form 4 filled with the SEC. Most recently Christopher exercised 15,000 units of RMD stock worth $386,250 on 24 May 2005.

The largest trade Christopher's ever made was exercising 15,000 units of Resmed stock on 24 May 2005 worth over $386,250. On average, Christopher trades about 625 units every 0 days since 2003. As of 24 May 2005 Christopher still owns at least 16,000 units of Resmed stock.

You can see the complete history of Christopher Bartlett stock trades at the bottom of the page.



What's Christopher Bartlett's mailing address?

Christopher's mailing address filed with the SEC is , , , , .

Insiders trading at Resmed

Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, and David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.



What does Resmed do?

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.



Complete history of Christopher Bartlett stock trades at Flowserve and Resmed

Insider
Trans.
Transaction
Total value
Christopher Bartlett
Director
Option $386,250
24 May 2005


Resmed executives and stock owners

Resmed executives and other stock owners filed with the SEC include: